** Shares of Lyell Immunopharma LYEL.O rise 15% to $11.70 premarket
** Co says 88% of patients with a type of blood cancer who were given LYEL's experimental cell therapy, called LYL314, had their tumors shrink or disappear after treatment in an early- to mid-stage trial
** LYEL says 72% of patients experienced a complete disappearance of all signs of their cancer following treatment with the therapy
** Up to last close, stock had fallen 21% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。